PCSK9 inhibitors were prescribed for 11.5% (n = 10) within the terms of the drug reimbursement scheme, which required the cumulative fulfillment of the following criteria: age 18 or above; diagnosis of FH with more than 8 points on the DLCN scale; meeting the eligibility criteria for LDL apheresis treatment; and for patients already treated, meeting these criteria at the time of initiation of LDL apheresis treatment. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.